Oncotelic

Oncotelic company information, Employees & Contact Information

Updated May 2026

Quick answer

Oncotelic is a Biotechnology Research company. It has approximately 23 employees on record. Contact data was last refreshed in May 2026. Find Oncotelic's verified employee emails, phone numbers, headquarters address, and key decision makers below.

Explore related pages

Related company profiles:

Oncotelic /Mateon is a convergent of PointR AI clustercomputing, Oncotelic antisense platform, and Mateon vascular disrupting agent. Lead asset OT-101 is an antisense against TGF-beta for cancer, covid-19, and other viruses

Company Details

Employees
23
Address
29397 Agoura Rd,
Phone
(650) 635-7000
Email
in****@****lic.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Agoura Hills, California
Looking for a particular Oncotelic employee's phone or email?

Oncotelic Questions

News

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Working to - GlobeNewswire

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Working to GlobeNewswire

Oncotelic (OTCQB: OTLC) to present 3 SABCS 2025 Sapu003 abstracts on IV everolimus - Stock Titan

Oncotelic (OTCQB: OTLC) to present 3 SABCS 2025 Sapu003 abstracts on IV everolimus Stock Titan

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Building Breakthrough Portfolio Aimed at Transforming Cancer, Rare Disease Treatments - Yahoo Finance

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Building Breakthrough Portfolio Aimed at Transforming Cancer, Rare Disease Treatments Yahoo Finance

Oncotelic Therapeutics Highlights Peer‑Reviewed Publication Linking TGFB2 to Survival in Younger Pancreatic Cancer Patients - Yahoo Finance

Oncotelic Therapeutics Highlights Peer‑Reviewed Publication Linking TGFB2 to Survival in Younger Pancreatic Cancer Patients Yahoo Finance

Oncotelic Therapeutics Highlights 2 Years of Clinical and Regulatory Advancements Across Late-Stage Pipeline - GlobeNewswire

Oncotelic Therapeutics Highlights 2 Years of Clinical and Regulatory Advancements Across Late-Stage Pipeline GlobeNewswire

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Creating - GlobeNewswire

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Creating GlobeNewswire

Sapu Nano Unveils First-in-Human Clinical Trial of Sapu-003 - GlobeNewswire

Sapu Nano Unveils First-in-Human Clinical Trial of Sapu-003 GlobeNewswire

Oncotelic Therapeutics Showcases Robust Pipeline and - GlobeNewswire

Oncotelic Therapeutics Showcases Robust Pipeline and GlobeNewswire

Oncotelic Therapeutics Announces Successful Completion of Phase 1 Trial of OT-101 and IL-2, Highlights Findings at SWCR 2025 Conference - GlobeNewswire

Oncotelic Therapeutics Announces Successful Completion of Phase 1 Trial of OT-101 and IL-2, Highlights Findings at SWCR 2025 Conference GlobeNewswire

Oncotelic Accesses Rapid IND Development Platform through Partnership with Medicilon - GlobeNewswire

Oncotelic Accesses Rapid IND Development Platform through Partnership with Medicilon GlobeNewswire

Oncotelic Therapeutics Announces Opening of GMP Manufacturing Plant - Yahoo Finance

Oncotelic Therapeutics Announces Opening of GMP Manufacturing Plant Yahoo Finance

Oncotelic Therapeutics, Inc. to Sell Its Necroptosis Cancer Therapy Assets to Mosaic ImmunoEngineering, Inc. - GlobeNewswire

Oncotelic Therapeutics, Inc. to Sell Its Necroptosis Cancer Therapy Assets to Mosaic ImmunoEngineering, Inc. GlobeNewswire

Oncotelic Participating at 2023 BIO International Convention - Yahoo Finance

Oncotelic Participating at 2023 BIO International Convention Yahoo Finance

Oncotelic Initiates Clinical Trials Evaluating OT-101 against Metastatic Pancreatic Cancer - GlobeNewswire

Oncotelic Initiates Clinical Trials Evaluating OT-101 against Metastatic Pancreatic Cancer GlobeNewswire

Oncotelic Announces Pipeline Presentation and IPO Update of Sapu Therapeutics at the 2022 BIO International Convention - Yahoo Finance

Oncotelic Announces Pipeline Presentation and IPO Update of Sapu Therapeutics at the 2022 BIO International Convention Yahoo Finance

ONCOTELIC ACQUIRES FAST TO MARKET LATE-STAGE DRUG CANDIDATE - GlobeNewswire

ONCOTELIC ACQUIRES FAST TO MARKET LATE-STAGE DRUG CANDIDATE GlobeNewswire

ONCOTELIC THERAPEUTICS, INC. (FORMERLY MATEON THERAPEUTICS, INC.) NAME AND SYMBOL CHANGE. - GlobeNewswire

ONCOTELIC THERAPEUTICS, INC. (FORMERLY MATEON THERAPEUTICS, INC.) NAME AND SYMBOL CHANGE. GlobeNewswire

Oncotelic Participating at Biotechgate Digital Partnering - GlobeNewswire

Oncotelic Participating at Biotechgate Digital Partnering GlobeNewswire

Top Oncotelic Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant